Aldeyra Therapeutics is a
biotechnology company developing a novel drug platform of drug candidates
designed to trap free aldehydes, which are naturally occurring chemical species
considered to be inflammatory-inducing, toxic links to many diseases, including
autoimmune, inflammatory, and neurological diseases.
Aldeyra has developed a
suite of “traps” designed to capture and eliminate free aldehydes, which
ideally would allow for the treatment and prevention of disease, as well as
slowed progression of chronic disease. In animal testing, the company’s lead
compound, NS2, was generally safe and well-tolerated topically and
systemically. In a phase 1evaluation trial in human subjects, NS2 was safe and
well-tolerated when administered as an eye drop.
In 2014, the company plans
to initiate the following studies for NS2: phase II trials in discoid lupus,
acute anterior uveitis, and ocular rosacea; a phase III trial in the rare
Sjogren-Larsson syndrome; and a phase I study to test the safety of an oral
formulation of the candidate. For rare diseases, Aldeyra intends to pursue
orphan drug designation of its platform from the United States Food and Drug
Administration (FDA).
To raise capital to fund its
clinical trials and to develop additional aldehyde traps for the treatment of
other diseases, Aldeyra today made its market debut on the Nasdaq exchange with
a $31.3 million initial public offering (IPO) of 2.2 million shares priced at
$10-$11 a piece.
“We believe there is
significant unmet medical need for the therapies we intend to develop. We are
not aware of any therapy that has been approved by the United States Food and
Drug Administration, or the FDA, for SLS or ocular rosacea with meibomian gland
dysfunction. … We believe that NS2 has the potential to be the first in class
of aldehyde traps for the diseases described above and potentially for
inflammatory and other diseases generally. None of our products have been
approved for sale in the United States or elsewhere,” the company stated, as
reported by Nasdaq.com.
For more information visit
http://www.aldeyra.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
